/ People /
As Managing Partner of Medison Ventures and as VP of Corporate development for the Medison Group, Gil applies his vast experience in business strategy, consulting, corporate finance, private equity and capital markets, gained from his time as Vice President of Shamrock, a private equity fund, and as board member of several Israeli and international companies. Gil holds an MBA from the Recanati Business School at Tel Aviv University and a BSc from the Technion.
DR. YAEL GRUENBAUM-COHEN
Prior to joining Medison Ventures Yael spent four years as Medical Manager of Medison’s Rare Disease Division, where she supported over 17 products and pre-launched seven. Yael completed her DMD and Ph.D. at the Hebrew University where she studied mesenchymal stem cells migration before joining as postdoctoral fellow to the Weizmann Institute of Science to investigate the underlying molecular genetics of muscle stem cell fusion.
DR. GOOZY HARTOG
Goozy brings to his role in Medison Ventures experience gained as a Consultant with the Boston Consulting Group, where he consulted on multiple pharma projects for multinational companies. Prior to that Goozy worked with the Solution Lab to support early stage biotech and medical device companies. Goozy completed his Ph.D. in neurobiology at the New York Medical College where he studied the underlying biology of posttraumatic stress disorder.
DR. MATAN OFIR
Prior to joining Medison Ventures Matan was part of the business development team of Cold Genesys, a US-based clinical stage biotech company. Matan holds a Ph.D. in biology from Bar-Ilan University where he studied transcription mechanisms and later he completed a postdoctoral fellowship looking at the role of long non-coding RNAs in the innate immune response at City of Hope National Medical Center in California. Matan also holds a Post-doctoral Professional Masters in Bioscience Management from the Keck Graduate Institute.
DR. ASSI TSUR
Assi is the Portfolio Manager of Medison’s healthcare-focused hedge fund. Before joining Medison, Assi was an equity analyst at Nexthera Capital, a New-York based biotech-focused Hedge Fund. Prior to that, Assi served as a Biotech Consultant at L1 Capital, New York, and as a Biotech Analyst at Natalitix. Assi holds a Ph.D. from Tel Aviv University where he studied the role of the SUMO pathway in epidermal morphogenesis.
Dr. Itsik Francis
Itsik brings to Medison Ventures an extensive knowledge gained as a director at Ariel University’s tech transfer office. During his role at Ariel, Itsik performed technology scouting, commercialization, and raised funding from the Israel Innovation Authority. Prior to Ariel, Itsik worked as an Ass. Research Scientist at Columbia University, working on a variety of drug development projects. Itsik holds a Ph.D. from University College London where he studied epigenetic mechanisms in Alzheimer’s Disease.
Dr. Inna Grodzovski
Before joining Medison Ventures, Inna worked as a client strategist at the FreeMind group, a life-science non-dilutive funding consultancy firm, assisting biotech companies and academic groups to secure non-dilutive funding from US federal agencies like NIH, DOD and private foundations. Inna holds a Ph.D. in cellular and molecular biochemistry focusing on chimeric protein targeted cancer therapy from the Hebrew university and a postdoctoral fellowship from Mount Sinai, in the field of transplant tolerance.
Tamar supports all aspects of coordination and logistics. Prior to joining Medison Ventures, Tami worked at Janssen Pharmaceutical as a Compliance Assistant. Tami holds a M.Sc in Biotechnology from the Hebrew University and a B.A in Biology from Bar Ilan University.